TrialPanorama/TrialPanorama-database huggingface dataset:
Study: 36577984

Group type: EXPERIMENTAL
Intervention: Bariatric surgery (Roux-en-Y gastric bypass after a 7-week low energy diet); 52-week follow-up
Number of subjects: 293

Group type: COMPARATOR
Intervention: Lifestyle intervention (59-week energy restricted diet and exercise program)
Number of subjects: 293

Group type: COMPARATOR
Intervention: Lifestyle intervention (20-week very-low energy diet/low energy diet)
Number of subjects: 293
Study: 36578002

Group type: EXPERIMENTAL
Intervention: Intervention (SHHC-2.0): Twice-weekly experiential classes focused on exercise, nutrition, and civic engagement.
Number of subjects: 182

Group type: COMPARATOR
Intervention: Control group (not specified in detail).
Number of subjects: 182
Study: 36578024

Group type: EXPERIMENTAL
Intervention: Virtual specialist conferences between endocrinologists and GPs (4 conferences over 12 months)
Number of subjects: 30

Group type: COMPARATOR
Intervention: Usual practice (control group)
Number of subjects: 30
Study: 36578040

Group type: EXPERIMENTAL
Intervention: 15 mg rivaroxaban
Number of subjects: 136
Study: 36578069

Group type: EXPERIMENTAL
Intervention: Single dose of intravenous phage (mixture of four anti-pseudomonal phages)
Number of subjects: 72

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 72
Study: 36578093

Group type: EXPERIMENTAL
Intervention: Community-based HIV and non-communicable disease care integrated within microfinance groups
Number of subjects: 105

Group type: EXPERIMENTAL
Intervention: Recruitment of microfinance groups
Number of subjects: 105

Group type: EXPERIMENTAL
Intervention: Stakeholder feedback
Number of subjects: 105
Study: 36578194

Group type: EXPERIMENTAL
Intervention: Infliximab 5 mg/kg intravenously at weeks 0, 2, and 6 (induction therapy)
Number of subjects: 33

Group type: EXPERIMENTAL
Intervention: Infliximab 5 mg/kg every 8 weeks during maintenance therapy
Number of subjects: 33
Study: 36578450

Group type: EXPERIMENTAL
Intervention: Occupational therapy-led fall prevention intervention
Number of subjects: 0

Group type: COMPARATOR
Intervention: Written education about fall prevention and alcohol use (control)
Number of subjects: 0
Study: 36578677

Group type: EXPERIMENTAL
Intervention: Adapted prolonged exposure psychotherapy (PE+)
Number of subjects: 0
Study: 36578806

Group type: EXPERIMENTAL
Intervention: Total IgG levels to Plasmodium falciparum schizont, assessed by enzyme-linked immunosorbent assay (ELISA)
Number of subjects: 252

Group type: EXPERIMENTAL
Intervention: Malaria incidence calculated from outpatient clinic data
Number of subjects: 252

Group type: COMPARATOR
Intervention: Comparison of incidence in high and low malaria transmission areas
Number of subjects: 252

Group type: COMPARATOR
Intervention: Comparison of total anti-schizont antibodies by gender and study year
Number of subjects: 252
Study: 36578832

Group type: EXPERIMENTAL
Intervention: 90-mg ticagrelor
Number of subjects: 0

Group type: COMPARATOR
Intervention: clopidogrel
Number of subjects: 0
Study: 36578904

Group type: EXPERIMENTAL
Intervention: OCT
Number of subjects: 439

Group type: EXPERIMENTAL
Intervention: OCTA
Number of subjects: 439

Group type: EXPERIMENTAL
Intervention: OCTA (3 × 3 mm superficial capillary plexus scan)
Number of subjects: 439

Group type: EXPERIMENTAL
Intervention: OCTA (deep capillary plexus scan)
Number of subjects: 439
Study: 36578916

Group type: EXPERIMENTAL
Intervention: Oral Ferrous Sulphate (FS) 200 mg three times a day for 12 weeks
Number of subjects: 54

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 54
Study: 36578945

Group type: EXPERIMENTAL
Intervention: Group-based training (GROUP)
Number of subjects: 54

Group type: COMPARATOR
Intervention: Home-based training (HOME)
Number of subjects: 54

Group type: EXPERIMENTAL
Intervention: Both GROUP and HOME
Number of subjects: 54
Study: 36579179

Group type: EXPERIMENTAL
Intervention: Swiss low back acupuncture (SLBA) - 9-week therapy, 15 sessions total (weeks 1-6: two sessions/week, weeks 7-9: one session/week)
Number of subjects: 110

Group type: COMPARATOR
Intervention: Standard acupuncture (SA) - 9-week therapy, 15 sessions total (weeks 1-6: two sessions/week, weeks 7-9: one session/week)
Number of subjects: 110
Study: 36579349

Group type: EXPERIMENTAL
Intervention: Compound 7460-0250
Number of subjects: 1
Study: 36579375

Group type: EXPERIMENTAL
Intervention: DOAC
Number of subjects: 260

Group type: COMPARATOR
Intervention: Warfarin
Number of subjects: 260

Group type: COMPARATOR
Intervention: No OAC
Number of subjects: 260
Study: 36579379

Group type: EXPERIMENTAL
Intervention: Sleep apnea (SA)
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Coronary artery disease (CAD)
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Sleep apnea (SA) in patients without CAD
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Sleep apnea (SA) in patients with CAD
Number of subjects: 0
Study: 36579406

Group type: EXPERIMENTAL
Intervention: VBAF detection algorithm
Number of subjects: 291
Study: 36579443

Group type: EXPERIMENTAL
Intervention: 5 mg/kg of intramuscular nandrolone decanoate every 15 days for 2 years
Number of subjects: 17
Study: 36579470

Group type: EXPERIMENTAL
Intervention: Body composition assessment using psoas area and density measurements
Number of subjects: 2066

Group type: EXPERIMENTAL
Intervention: Recursive partitioning analysis (RPA) classification tree
Number of subjects: 2066

Group type: EXPERIMENTAL
Intervention: Body composition as a factor in mortality prediction
Number of subjects: 2066
Study: 36579494

Group type: EXPERIMENTAL
Intervention: Oral amoxicillin for 3 days
Number of subjects: 4984

Group type: COMPARATOR
Intervention: Cotrimoxazole for 5 days
Number of subjects: 4984
Study: 36579617

Group type: EXPERIMENTAL
Intervention: Ambrisentan low dose
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Ambrisentan high dose
Number of subjects: 0

Group type: COMPARATOR
Intervention: Ambrisentan (both doses)
Number of subjects: 0
Study: 36579743

Group type: EXPERIMENTAL
Intervention: Brigatinib 180 mg once daily (days 9-28)
Number of subjects: 10

Group type: EXPERIMENTAL
Intervention: Brigatinib coadministered with midazolam
Number of subjects: 10
Study: 36579756

Group type: EXPERIMENTAL
Intervention: Subepithelial connective tissue graft (SCTG)
Number of subjects: 0

Group type: COMPARATOR
Intervention: No connective tissue graft (NGG)
Number of subjects: 0
Study: 36579859

Group type: EXPERIMENTAL
Intervention: Stage I model
Number of subjects: 654

Group type: EXPERIMENTAL
Intervention: Stage II model
Number of subjects: 654

Group type: EXPERIMENTAL
Intervention: External validation of Stage I model
Number of subjects: 654

Group type: EXPERIMENTAL
Intervention: External validation of Stage II model
Number of subjects: 654
Study: 36580029

Group type: EXPERIMENTAL
Intervention: Sucrosomial® iron (60 mg/day for one month)
Number of subjects: 594

Group type: COMPARATOR
Intervention: Routine care (Control group)
Number of subjects: 594
Study: 36580073

Group type: EXPERIMENTAL
Intervention: PTBi intervention package (provider mentoring using PRONTO simulation, team training, quality improvement collaboratives)
Number of subjects: 29442

Group type: COMPARATOR
Intervention: Control group (modified WHO Safe Childbirth Checklist, data strengthening)
Number of subjects: 29442

Group type: EXPERIMENTAL
Intervention: PTBi intervention package
Number of subjects: 29442
Study: 36580304

Group type: EXPERIMENTAL
Intervention: Bimodal visual-olfactory training with patient-preferred scents
Number of subjects: 275

Group type: COMPARATOR
Intervention: Unimodal olfactory training with physician-assigned scents
Number of subjects: 275
Study: 36580332

Group type: EXPERIMENTAL
Intervention: Mechanical ventilation on postnatal day 14
Number of subjects: 874

Group type: EXPERIMENTAL
Intervention: Severe bronchopulmonary dysplasia (BPD) or death
Number of subjects: 874

Group type: EXPERIMENTAL
Intervention: Time to return to birth weight (BW)
Number of subjects: 874

Group type: EXPERIMENTAL
Intervention: Peak fluid balance (FB) during the first 14 postnatal days
Number of subjects: 874
Study: 36580379

Group type: EXPERIMENTAL
Intervention: Newly diagnosed patients with IIPs
Number of subjects: 600

Group type: EXPERIMENTAL
Intervention: Progressive fibrosing-ILD patients
Number of subjects: 600
Study: 36580441

Group type: EXPERIMENTAL
Intervention: Mean arterial pressure (MAP) ≤81.5 mmHg
Number of subjects: 450

Group type: EXPERIMENTAL
Intervention: Age
Number of subjects: 450

Group type: EXPERIMENTAL
Intervention: History of heart failure
Number of subjects: 450

Group type: EXPERIMENTAL
Intervention: Simplified Pulmonary Embolism Severity Index
Number of subjects: 450

Group type: EXPERIMENTAL
Intervention: Systemic thrombolysis
Number of subjects: 450

Group type: EXPERIMENTAL
Intervention: MAP ≤81.5 mmHg at admission
Number of subjects: 450

Group type: EXPERIMENTAL
Intervention: Deteriorating group
Number of subjects: 450
Study: 36580650

Group type: EXPERIMENTAL
Intervention: anaprazole 20 mg once daily for 4 weeks
Number of subjects: 448

Group type: COMPARATOR
Intervention: rabeprazole 10 mg + anaprazole placebo
Number of subjects: 448
Study: 36581186

Group type: EXPERIMENTAL
Intervention: Lopinavir/ritonavir (LPV/r) 400 mg/100 mg twice daily for 14 days
Number of subjects: 448

Group type: COMPARATOR
Intervention: Placebo (Plb)
Number of subjects: 448
Study: 36581413

Group type: EXPERIMENTAL
Intervention: Cochlear implant (CI) and hearing aid (HA) in a bimodal solution (CI+HA)
Number of subjects: 60

Group type: COMPARATOR
Intervention: Bilateral hearing aids (HA+HA)
Number of subjects: 60
Study: 36581426

Group type: EXPERIMENTAL
Intervention: Prediabetes based on HbA1c criteria (5.7%-6.4%)
Number of subjects: 291

Group type: EXPERIMENTAL
Intervention: Female gender
Number of subjects: 291
Study: 36581419

Group type: EXPERIMENTAL
Intervention: 12-week multimodal progressive exercise intervention delivered online
Number of subjects: 1500
Study: 36581428

Group type: EXPERIMENTAL
Intervention: Individualised follow-up (patients attend outpatient clinic on their own initiative)
Number of subjects: 0

Group type: COMPARATOR
Intervention: Standardised follow-up (continuing the 5-year guideline-prescribed schedule)
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Individualised follow-up
Number of subjects: 0

Group type: COMPARATOR
Intervention: Standardised follow-up
Number of subjects: 0
Study: 36581796

Group type: EXPERIMENTAL
Intervention: Praziquantel (40 mg/kg)
Number of subjects: 777

Group type: COMPARATOR
Intervention: Control group (no treatment)
Number of subjects: 777
Study: 36581833

Group type: EXPERIMENTAL
Intervention: Cardiac Anxiety Questionnaire (CAQ)
Number of subjects: 930
Study: 36581874

Group type: EXPERIMENTAL
Intervention: Preoperative carbohydrates (CHO) supplement, 50 g carbohydrates orally the evening before surgery (20:00-24:00)
Number of subjects: 62

Group type: COMPARATOR
Intervention: Control group (CTRL), fasting after 20:00 the evening before surgery
Number of subjects: 62
Study: 36581878

Group type: EXPERIMENTAL
Intervention: Efavirenz 50 mg
Number of subjects: 5

Group type: EXPERIMENTAL
Intervention: Efavirenz 200 mg
Number of subjects: 5

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 5
Study: 36581881

Group type: EXPERIMENTAL
Intervention: Light Gradient Boosting Machine (LightGBM)
Number of subjects: 6891

Group type: EXPERIMENTAL
Intervention: Multilayer perceptron (MLP)
Number of subjects: 6891

Group type: EXPERIMENTAL
Intervention: LightGBM
Number of subjects: 6891

Group type: EXPERIMENTAL
Intervention: MLP
Number of subjects: 6891

Group type: EXPERIMENTAL
Intervention: Final ensemble model after transfer learning and ensemble learning
Number of subjects: 6891
Study: 36581893

Group type: EXPERIMENTAL
Intervention: Metformin (n=194)
Number of subjects: 373

Group type: COMPARATOR
Intervention: Placebo (n=179)
Number of subjects: 373
Study: 36581902

Group type: EXPERIMENTAL
Intervention: Osteopathic manipulative treatment (OMT) associated with pain neuroscience education (PNE) and clinical hypnosis (CH)
Number of subjects: 0

Group type: COMPARATOR
Intervention: PNE, CH, and sham therapy
Number of subjects: 0
Study: 36581901

Group type: EXPERIMENTAL
Intervention: Combined papillary muscle relocation and ring annuloplasty
Number of subjects: 97
Study: 36581914

Group type: EXPERIMENTAL
Intervention: Stereotactic ablative body radiotherapy (SABR) - 5 fractions of 8 Gy
Number of subjects: 0

Group type: COMPARATOR
Intervention: Best supportive care
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: SABR
Number of subjects: 0
Study: 36581937

Group type: EXPERIMENTAL
Intervention: Non-invasive treatment
Number of subjects: 0

Group type: COMPARATOR
Intervention: Surgical decompression
Number of subjects: 0
Study: 36581960

Group type: EXPERIMENTAL
Intervention: Acupuncture
Number of subjects: 300

Group type: COMPARATOR
Intervention: Massage
Number of subjects: 300
Study: 36581962

Group type: EXPERIMENTAL
Intervention: Traumatic lesion on head CT
Number of subjects: 20000

Group type: EXPERIMENTAL
Intervention: Clinically significant lesion
Number of subjects: 20000
Study: 36581983

Group type: EXPERIMENTAL
Intervention: Hypofractionated regimen of 2.67 Gy for 16 fractions
Number of subjects: 801

Group type: COMPARATOR
Intervention: Conventional regimen of 2 Gy for 25 fractions
Number of subjects: 801
Study: 36581996

Group type: EXPERIMENTAL
Intervention: Active irrigation in external ventricular drainage (IRRAflow)
Number of subjects: 58

Group type: COMPARATOR
Intervention: Passive external ventricular drainage (EVD)
Number of subjects: 58
Study: 36582001

Group type: EXPERIMENTAL
Intervention: MR-HIFU
Number of subjects: 216

Group type: COMPARATOR
Intervention: EBRT
Number of subjects: 216

Group type: EXPERIMENTAL
Intervention: MR-HIFU + EBRT
Number of subjects: 216
Study: 36582225

Group type: EXPERIMENTAL
Intervention: Immune checkpoint blockade (ICB) immunotherapy
Number of subjects: 41

Group type: COMPARATOR
Intervention: Unvaccinated control group
Number of subjects: 41
Study: 36582243

Group type: EXPERIMENTAL
Intervention: Cavrotolimod (5, 10, 12.5, and 18.8 µg/kg)
Number of subjects: 16
Study: 36582297

Group type: EXPERIMENTAL
Intervention: Nintendo Switch RingFit Adventure (RFA) exergame-based exercise, details on dosage and duration not available.
Number of subjects: 0

Group type: COMPARATOR
Intervention: Control group not specified, details not available.
Number of subjects: 0
Study: 36582390

Group type: EXPERIMENTAL
Intervention: Tai Chi training (1 hour per day, 5 days per week for 12 weeks)
Number of subjects: 82

Group type: COMPARATOR
Intervention: Waiting list control group (delayed Tai Chi training)
Number of subjects: 82
Study: 36582423

Group type: EXPERIMENTAL
Intervention: Proton beam therapy (PBT)
Number of subjects: 20

Group type: COMPARATOR
Intervention: Photon beam therapy (SCRT with photons)
Number of subjects: 20
Study: 36582659

Group type: EXPERIMENTAL
Intervention: Hypnosis (HYP)
Number of subjects: 232

Group type: EXPERIMENTAL
Intervention: Mindfulness Meditation (MM)
Number of subjects: 232

Group type: EXPERIMENTAL
Intervention: Christian Prayer (CP)
Number of subjects: 232

Group type: COMPARATOR
Intervention: Attention Control (CN)
Number of subjects: 232
Study: 36582742

Group type: EXPERIMENTAL
Intervention: NLRP3 variant G-allele carriers
Number of subjects: 1001
Study: 36583069

Group type: EXPERIMENTAL
Intervention: High-intensity yoga (HY)
Number of subjects: 30

Group type: EXPERIMENTAL
Intervention: Moderate-intensity yoga (MY)
Number of subjects: 30

Group type: COMPARATOR
Intervention: Sedentary control (CON)
Number of subjects: 30
Study: 36583171

Group type: EXPERIMENTAL
Intervention: Niraparib 200 mg or 300 mg once daily continuously and anlotinib 10 mg (12 mg before protocol amendment) once daily on days 1-14 of each 21-day cycle until disease progression or intolerable toxicity.
Number of subjects: 40

Group type: EXPERIMENTAL
Intervention: Niraparib plus anlotinib
Number of subjects: 40
Study: 36583350

Group type: EXPERIMENTAL
Intervention: Urine C3dg and sC5b-9-associated C9 neoantigen/creatinine ratios
Number of subjects: 88

Group type: EXPERIMENTAL
Intervention: Urine plasmin(ogen)
Number of subjects: 88

Group type: EXPERIMENTAL
Intervention: Urine albumin
Number of subjects: 88

Group type: EXPERIMENTAL
Intervention: Membrane-associated C3dg and C9 neoantigen
Number of subjects: 88

Group type: EXPERIMENTAL
Intervention: C3dg and C9 neoantigen
Number of subjects: 88

Group type: EXPERIMENTAL
Intervention: Urinary excretion of activated complement
Number of subjects: 88
Study: 36583355

Group type: EXPERIMENTAL
Intervention: Finerenone 10 mg once daily for 90 days
Number of subjects: 823

Group type: EXPERIMENTAL
Intervention: Finerenone 15 mg once daily for 90 days
Number of subjects: 823

Group type: EXPERIMENTAL
Intervention: Finerenone 20 mg once daily for 90 days
Number of subjects: 823
Study: 36583356

Group type: EXPERIMENTAL
Intervention: 24-h TTR for SBP (90-140 mmHg)
Number of subjects: 228

Group type: EXPERIMENTAL
Intervention: 24-h TTR for DBP (60-90 mmHg)
Number of subjects: 228

Group type: EXPERIMENTAL
Intervention: 24-h TTR for MAP
Number of subjects: 228

Group type: EXPERIMENTAL
Intervention: Increase in TTR of DBP
Number of subjects: 228

Group type: EXPERIMENTAL
Intervention: Increase in TTR of MAP
Number of subjects: 228

Group type: EXPERIMENTAL
Intervention: TTR of SBP in 130-180 mmHg and 110-160 mmHg ranges
Number of subjects: 228
Study: 36583436

Group type: EXPERIMENTAL
Intervention: Vascular Closure Device (VCD) implantation
Number of subjects: 1580

Group type: COMPARATOR
Intervention: Manual compression
Number of subjects: 1580

Group type: EXPERIMENTAL
Intervention: VCD implantation
Number of subjects: 1580
Study: 36583535

Group type: EXPERIMENTAL
Intervention: Palovarotene (5 mg daily for chronic treatment; 20 mg for flare-ups for 4 weeks, then 10 mg for ≥8 weeks, weight-adjusted if skeletally immature)
Number of subjects: 97

Group type: COMPARATOR
Intervention: NHS (natural history study participants, untreated beyond standard of care)
Number of subjects: 97
Study: 36583633

Group type: EXPERIMENTAL
Intervention: Eptinezumab 100 mg
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Eptinezumab 300 mg
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Eptinezumab
Number of subjects: 0

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 0
Study: 36583643

Group type: EXPERIMENTAL
Intervention: Oxalert with patient alerts (Monitor + Alert, N = 25)
Number of subjects: 49

Group type: COMPARATOR
Intervention: Oxalert without patient alerts (Monitor Only, N = 24)
Number of subjects: 49
Study: 36583684

Group type: EXPERIMENTAL
Intervention: Video-Feedback intervention
Number of subjects: 120

Group type: COMPARATOR
Intervention: Usual treatment
Number of subjects: 120
Study: 36583806

Group type: EXPERIMENTAL
Intervention: Relative increased hypermetabolism in VSS patients in the lingual gyrus and cuneus
Number of subjects: 0
Study: 36583920

Group type: EXPERIMENTAL
Intervention: Varus worsening trajectory (n=166)
Number of subjects: 1252

Group type: EXPERIMENTAL
Intervention: Valgus worsening trajectory (n=118)
Number of subjects: 1252

Group type: EXPERIMENTAL
Intervention: Neutral trajectory (n=378)
Number of subjects: 1252

Group type: EXPERIMENTAL
Intervention: Varus stable trajectory (n=328)
Number of subjects: 1252

Group type: EXPERIMENTAL
Intervention: Valgus stable trajectory (n=262)
Number of subjects: 1252
Study: 36583938

Group type: EXPERIMENTAL
Intervention: Apple Watch 7
Number of subjects: 201

Group type: EXPERIMENTAL
Intervention: Garmin Fenix 6 Pro
Number of subjects: 201

Group type: EXPERIMENTAL
Intervention: Withings ScanWatch
Number of subjects: 201

Group type: EXPERIMENTAL
Intervention: Fitbit Sense
Number of subjects: 201
Study: 36583990

Group type: EXPERIMENTAL
Intervention: SARS-CoV-2-vCTLs manufactured using CliniMACS Cytokine Capture System (CCS)
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: SARS-CoV-2-vCTLs manufactured using CliniMACS CCS
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: SARS-CoV-2-vCTLs
Number of subjects: 0
Study: 36583998

Group type: EXPERIMENTAL
Intervention: COVID-19 cohort
Number of subjects: 4427

Group type: COMPARATOR
Intervention: Control cohort
Number of subjects: 4427
Study: 36584022

Group type: EXPERIMENTAL
Intervention: Prone positioning (PP)
Number of subjects: 0
Study: 36584027

Group type: EXPERIMENTAL
Intervention: 12-week behavior change intervention delivered via videoconferencing technology by trained PA counsellors
Number of subjects: 0

Group type: COMPARATOR
Intervention: Usual care group (no intervention)
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: 12-week behavior change intervention
Number of subjects: 0
Study: 36584053

Group type: EXPERIMENTAL
Intervention: Erector spinae plane block (ESPB) with ropivacaine 0.75%, 0.35 ml.kg-1
Number of subjects: 102

Group type: COMPARATOR
Intervention: Thoracic paravertebral block (TPVB)
Number of subjects: 102

Group type: EXPERIMENTAL
Intervention: Erector spinae plane block (ESPB)
Number of subjects: 102
Study: 36584099

Group type: EXPERIMENTAL
Intervention: Favipiravir
Number of subjects: 712

Group type: COMPARATOR
Intervention: Nonrecipient group (no favipiravir)
Number of subjects: 712

Group type: EXPERIMENTAL
Intervention: Living alone (not an intervention but a factor)
Number of subjects: 712
Study: 36584183

Group type: EXPERIMENTAL
Intervention: Women with HIV (WWH)
Number of subjects: 20

Group type: COMPARATOR
Intervention: Women without HIV
Number of subjects: 20

Group type: EXPERIMENTAL
Intervention: Inflammatory monocyte activation among WWH
Number of subjects: 20
Study: 36584248

Group type: EXPERIMENTAL
Intervention: α-Lipoic Acid (ALA) 100 mg/d
Number of subjects: 0

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 0
Study: 36584579

Group type: EXPERIMENTAL
Intervention: Nerve-growth-factor injection
Number of subjects: 40

Group type: COMPARATOR
Intervention: Isotonic saline injection
Number of subjects: 40

Group type: EXPERIMENTAL
Intervention: Walking while reading on a smartphone
Number of subjects: 40

Group type: COMPARATOR
Intervention: Normal walking without neck pain
Number of subjects: 40
Study: 36584711

Group type: EXPERIMENTAL
Intervention: Machine learning model using early treatment data from STAR*D (baseline and first follow up) to predict remission rates at treatment step 1.
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Machine learning model using early treatment data from STAR*D to predict remission rates at treatment step 2.
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Machine learning model using early treatment data from STAR*D to predict remission rates at treatment step 3.
Number of subjects: 0
Study: 36584835

Group type: EXPERIMENTAL
Intervention: Discontinued treatment early
Number of subjects: 150

Group type: COMPARATOR
Intervention: Treated intermittently
Number of subjects: 150

Group type: COMPARATOR
Intervention: Treated continuously
Number of subjects: 150
Study: 36585028

Group type: EXPERIMENTAL
Intervention: Take-off
Number of subjects: 18

Group type: EXPERIMENTAL
Intervention: In-flight
Number of subjects: 18

Group type: EXPERIMENTAL
Intervention: Landing
Number of subjects: 18

Group type: COMPARATOR
Intervention: Take-off to In-flight comparison
Number of subjects: 18

Group type: COMPARATOR
Intervention: In-flight to Landing comparison
Number of subjects: 18

Group type: COMPARATOR
Intervention: Take-off to Landing comparison
Number of subjects: 18
Study: 36585126

Group type: EXPERIMENTAL
Intervention: OCT parameters
Number of subjects: 230

Group type: EXPERIMENTAL
Intervention: VF MD
Number of subjects: 230

Group type: EXPERIMENTAL
Intervention: wiVD
Number of subjects: 230